179 related articles for article (PubMed ID: 38348398)
1. Minimizing endogenous cryptic plasmids to construct antibiotic-free expression systems for
Zhou S; Zhao L; Zuo W; Zheng Y; Zhang P; Sun Y; Wang Y; Du G; Kang Z
Synth Syst Biotechnol; 2024 Mar; 9(1):165-175. PubMed ID: 38348398
[TBL] [Abstract][Full Text] [Related]
2. CRISPR-based curing and analysis of metabolic burden of cryptic plasmids in
Zainuddin HS; Bai Y; Mansell TJ
Eng Life Sci; 2019 Jun; 19(6):478-485. PubMed ID: 32625025
[No Abstract] [Full Text] [Related]
3. Improved cryptic plasmids in probiotic Escherichia coli Nissle 1917 for antibiotic-free pathway engineering.
Dong MM; Song L; Xu JQ; Zhu L; Xiong LB; Wei DZ; Wang FQ
Appl Microbiol Biotechnol; 2023 Aug; 107(16):5257-5267. PubMed ID: 37405431
[TBL] [Abstract][Full Text] [Related]
4. Plasmid Vectors for
Kan A; Gelfat I; Emani S; Praveschotinunt P; Joshi NS
ACS Synth Biol; 2021 Jan; 10(1):94-106. PubMed ID: 33301298
[No Abstract] [Full Text] [Related]
5. Expanding the toolbox of probiotic Escherichia coli Nissle 1917 for synthetic biology.
Ba F; Zhang Y; Ji X; Liu WQ; Ling S; Li J
Biotechnol J; 2024 Jan; 19(1):e2300327. PubMed ID: 37800393
[TBL] [Abstract][Full Text] [Related]
6. The flagellin hypervariable region is a potential flagella display domain in probiotic Escherichia coli strain Nissle 1917.
Yang Y; Yang Y; Ou B; Xia P; Zhou M; Li L; Zhu G
Arch Microbiol; 2016 Sep; 198(7):603-10. PubMed ID: 27071621
[TBL] [Abstract][Full Text] [Related]
7. Genetic engineering of probiotic Escherichia coli Nissle 1917 for clinical application.
Ou B; Yang Y; Tham WL; Chen L; Guo J; Zhu G
Appl Microbiol Biotechnol; 2016 Oct; 100(20):8693-9. PubMed ID: 27640192
[TBL] [Abstract][Full Text] [Related]
8. Development of strain-specific PCR reactions for the detection of the probiotic Escherichia coli strain Nissle 1917 in fecal samples.
Blum-Oehler G; Oswald S; Eiteljörge K; Sonnenborn U; Schulze J; Kruis W; Hacker J
Res Microbiol; 2003; 154(1):59-66. PubMed ID: 12576161
[TBL] [Abstract][Full Text] [Related]
9. Engineering E. coli strains using antibiotic-resistance-gene-free plasmids.
Amrofell MB; Rengarajan S; Vo ST; Ramirez Tovar ES; LoBello L; Dantas G; Moon TS
Cell Rep Methods; 2023 Dec; 3(12):100669. PubMed ID: 38086386
[TBL] [Abstract][Full Text] [Related]
10. Integration of Multiple Phage Attachment Sites System to Create the Chromosomal T7 System for Protein Production in
Cheng SY; Lin TH; Chen PT
J Agric Food Chem; 2022 Aug; 70(33):10239-10247. PubMed ID: 35960546
[No Abstract] [Full Text] [Related]
11. Redesign of an Escherichia coli Nissle treatment for phenylketonuria using insulated genomic landing pads and genetic circuits to reduce burden.
Triassi AJ; Fields BD; Monahan CE; Means JM; Park Y; Doosthosseini H; Padmakumar JP; Isabella VM; Voigt CA
Cell Syst; 2023 Jun; 14(6):512-524.e12. PubMed ID: 37348465
[TBL] [Abstract][Full Text] [Related]
12. Efficient markerless integration of genes in the chromosome of probiotic E. coli Nissle 1917 by bacterial conjugation.
Seco EM; Fernández LÁ
Microb Biotechnol; 2022 May; 15(5):1374-1391. PubMed ID: 34755474
[TBL] [Abstract][Full Text] [Related]
13. Enhancing the antibacterial function of probiotic
Bartram E; Asai M; Gabant P; Wigneshweraraj S
Appl Environ Microbiol; 2023 Nov; 89(11):e0097523. PubMed ID: 37930328
[TBL] [Abstract][Full Text] [Related]
14. Stable expression of HIV-1 MPER extended epitope on the surface of the recombinant probiotic bacteria Escherichia Coli Nissle 1917 using CRISPR/Cas9.
Ninyio N; Schmitt K; Sergon G; Nilsson C; Andersson S; Scherbak N
Microb Cell Fact; 2024 Feb; 23(1):39. PubMed ID: 38311724
[TBL] [Abstract][Full Text] [Related]
15. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial.
Petersen AM; Mirsepasi H; Halkjær SI; Mortensen EM; Nordgaard-Lassen I; Krogfelt KA
J Crohns Colitis; 2014 Nov; 8(11):1498-505. PubMed ID: 24972748
[TBL] [Abstract][Full Text] [Related]
16. Construction of a new T7 promoter compatible Escherichia coli Nissle 1917 strain for recombinant production of heme-dependent proteins.
Fiege K; Frankenberg-Dinkel N
Microb Cell Fact; 2020 Oct; 19(1):190. PubMed ID: 33023596
[TBL] [Abstract][Full Text] [Related]
17. Prospective and challenges of live bacterial therapeutics from a superhero
Effendi SSW; Ng IS
Crit Rev Microbiol; 2023 Sep; 49(5):611-627. PubMed ID: 35947523
[No Abstract] [Full Text] [Related]
18. A Novel Nonantibiotic,
Terrinoni M; Nordqvist SL; Källgård S; Holmgren J; Lebens M
Appl Environ Microbiol; 2018 Feb; 84(4):. PubMed ID: 29222103
[TBL] [Abstract][Full Text] [Related]
19. Engineering Escherichia coli Nissle 1917 as a microbial chassis for therapeutic and industrial applications.
Yu M; Hu S; Tang B; Yang H; Sun D
Biotechnol Adv; 2023 Oct; 67():108202. PubMed ID: 37343690
[TBL] [Abstract][Full Text] [Related]
20. Engineering the probiotic bacterium Escherichia coli Nissle 1917 as an efficient cell factory for heparosan biosynthesis.
Hu S; Zhao L; Hu L; Xi X; Zhang Y; Wang Y; Chen J; Chen J; Kang Z
Enzyme Microb Technol; 2022 Aug; 158():110038. PubMed ID: 35453037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
